Distinguished in Angiosarcoma

Dr. Mahvish U. Muzaffar

Hematology Oncology | Hematology
Vidant Medical Group LLC
226 Academy St S, 
Ahoskie, NC 
Accepting New Patients
Distinguished in Angiosarcoma
Vidant Medical Group LLC
226 Academy St S, 
Ahoskie, NC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Mahvish Muzaffar is a Hematologist Oncology specialist and a Hematologist in Ahoskie, North Carolina. Dr. Muzaffar is rated as a Distinguished provider by MediFind in the treatment of Angiosarcoma. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Angiosarcoma, Inflammatory Breast Cancer, and Bone Marrow Aspiration. Dr. Muzaffar is currently accepting new patients.

Her clinical research consists of co-authoring 60 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Licenses
Internal Medicine in NC
Hospital Affiliations
Ecu Health Medical Center
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Sentara Healthcare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Trillium
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

VIDANT MEDICAL GROUP LLC
226 Academy St S, Ahoskie, NC 27910

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase 2 Study of Pevonedistat in Combination With Carboplatin and Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma
A Phase 2 Study of Pevonedistat in Combination With Carboplatin and Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Drug
Study Drugs: Carboplatin, Paclitaxel, Pevonedistat
Study Phase: Phase 2
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Procedure, Drug
Study Drugs: Atezolizumab, 5-Fluorouracil, Leucovorin, Oxaliplatin
Study Phase: Phase 3
Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions
Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2025
Intervention Type: Other, Behavioral
Study Phase: Phase 3
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Enrollment Status: Completed
Publish Date: March 17, 2025
Intervention Type: Drug, Biological
Study Drugs: Margetuximab, Trastuzumab, Capecitabine, Eribulin, Gemcitabine, Vinorelbine
Study Phase: Phase 3
Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Other, Dietary supplement, Drug
Study Drugs: Bevacizumab, Oxaliplatin, Leucovorin calcium, Fluorouracil, Irinotecan hydrochloride, Irinotecan
Study Phase: Phase 3
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Radiation, Procedure
Study Phase: Phase 3
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Other
Study Phase: Phase 3
Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: a Phase III Study
Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: a Phase III Study
Enrollment Status: Active_not_recruiting
Publish Date: January 10, 2025
Intervention Type: Drug
Study Drugs: Fulvestrant, Anastrozole
Study Phase: Phase 3
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 03, 2024
Intervention Type: Drug, Other
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Paclitaxel
Study Phase: Phase 3
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma
Enrollment Status: Completed
Publish Date: August 14, 2023
Intervention Type: Drug
Study Drugs: tucatinib, capecitabine, trastuzumab
Study Phase: Phase 2
View 9 Less Clinical Trials

60 Total Publications

Ferroelectrically Switchable Half-Quantized Hall Effect.
Ferroelectrically Switchable Half-Quantized Hall Effect.
Journal: Nano letters
Published: April 24, 2025
Similar Doctors
Distinguished in Angiosarcoma
Dr. Heather R. White
Hematology Oncology | Hematology | Oncology
Distinguished in Angiosarcoma
Dr. Heather R. White
Hematology Oncology | Hematology | Oncology

Physicians East PA

1850 W Arlington Blvd, 
Greenville, NC 
 (52.8 miles away)
252-413-6740
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Heather White is a Hematologist Oncology specialist and a Hematologist in Greenville, North Carolina. Dr. White is rated as a Distinguished provider by MediFind in the treatment of Angiosarcoma. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Inflammatory Breast Cancer, Bone Graft, and Vertebroplasty. Dr. White is currently accepting new patients.

Distinguished in Angiosarcoma
Dr. Thomas A. Alberico
Hematology Oncology | Hematology | Oncology
Distinguished in Angiosarcoma
Dr. Thomas A. Alberico
Hematology Oncology | Hematology | Oncology

Virginia Oncology Associates

5900 Lake Wright Dr, 
Norfolk, VA 
 (59.8 miles away)
757-466-8683
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Thomas Alberico is a Hematologist Oncology specialist and a Hematologist in Norfolk, Virginia. Dr. Alberico is rated as a Distinguished provider by MediFind in the treatment of Angiosarcoma. His top areas of expertise are Paget Disease of the Breast, Breast Cancer, Colorectal Cancer, Lynch Syndrome, and Bone Marrow Aspiration. Dr. Alberico is currently accepting new patients.

Distinguished in Angiosarcoma
Dr. Michael T. Hopkins
Hematology Oncology | Hematology | Oncology
Distinguished in Angiosarcoma
Dr. Michael T. Hopkins
Hematology Oncology | Hematology | Oncology

Vidant Medical Group LLC

500 Academy St S, Vidant Roanoke Chowan Hosp, 
Ahoskie, NC 
 (0.2 miles away)
252-209-3708
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Michael Hopkins is a Hematologist Oncology specialist and a Hematologist in Ahoskie, North Carolina. Dr. Hopkins is rated as a Distinguished provider by MediFind in the treatment of Angiosarcoma. His top areas of expertise are Angiosarcoma, Monoclonal Gammopathy of Undetermined Significance (MGUS), Schnitzler Syndrome, and Inflammatory Breast Cancer. Dr. Hopkins is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Muzaffar's expertise for a condition
ConditionClose
    View All 10 Advanced Conditions
    View All 40 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile